Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD64 CAR T Cells in Relapsed/Refractory AML
NCT07347418Phase 1Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Sep 2026
- Primary completion
- Jun 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD64 CAR T cells in acute myeloid leukemia (AML), sponsored by University of Colorado Denver. Primary endpoint: Maximum Tolerated Dose. Started Sep 2026; status: recruiting.
02
Drugs
CD64 CAR T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07347418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347418.